Latest Product Launch News

Aguia Resources has secured key mining concessions in Brazil, setting the stage for operational licensing and commissioning of its Tres Estradas phosphate mine by April 2026.

Audeara Limited has initiated three new white-label Auracast™ programs with Clinico Inc., alongside launching its BT-03 Audio Broadcaster in Australia, marking a significant step in scaling its audio technology globally.

FBR Limited reports a significant reduction in half-year losses alongside new robotic product launches, yet cash flow challenges raise questions about its financial sustainability.

De.mem Limited reported a 20% increase in revenue to $29.9 million for FY2025, alongside a reduced net loss and its first full-year positive adjusted EBITDA. The company also completed the acquisition of Core Chemicals, expanding its specialty chemicals footprint in the gold mining sector.

Atomos Limited has reported a profitable first half of FY26 with revenue up 28%, driven by strong sales and cost discipline. The company reaffirms its full-year guidance, anticipating further growth and positive cash flow in the second half.

HighCom Limited has revealed a sharp downturn in its half-year results, with revenue plunging 59% and a $6.8 million loss after tax, driven by US government shutdown impacts. The company is banking on new lightweight XTclave® armour products to fuel a recovery in the second half of FY26.

Block, Inc. reported robust financial results for 2025, driven by Cash App and Square growth, while announcing a significant workforce reduction to accelerate AI-driven innovation and efficiency.

ReNerve Limited reported a half-year loss of $2.72 million, up 47% from last year, as it expands its nerve repair product portfolio and secures new regulatory approvals in Asia-Pacific.

Qoria Limited reported a 25% revenue increase to nearly $69 million for H1 FY2026 but also a widening net loss of $24.5 million. The company announced a transformative merger with US-based Aura to create a global digital safety leader.

Immuron Limited reported a narrower half-year loss alongside record sales growth and FDA approval for its IMM-529 drug candidate, signalling promising clinical and commercial momentum.

Compumedics Limited has reported a robust half-year performance, with revenue climbing 32% to $31 million and a return to profitability, driven by strong MEG system sales and SaaS growth.

VEEM Ltd posted a significant half-year loss of $19.5 million, driven by a 30% revenue decline and a $24.8 million impairment on gyro product development. Despite setbacks, new product launches and US defence market progress offer a hopeful outlook.